Triad Isotopes Announces the creation of its Institute of Clinical Learning.
Triad Isotopes attracts industry thought leaders to new group dedicated to academic based research, publishing and training
Orlando Florida, October 10, 2007 – Triad Isotopes, Inc. headquartered in Orlando Florida today announced the creation of its Institute of Clinical Learning, and the release of the Institute’s first research findings and subsequent publication.
The Institute of Clinical Learning was developed by Triad to provide the market an academic based resource dedicated to advancing Nuclear Medicine through research, publishing and training. The Institute is comprised of clinicians, technologists, nuclear pharmacists and professionals that bring over 100 years of nuclear medicine, nuclear cardiology, PET / CT, nuclear pharmacy and regulatory expertise as part of the Triad Isotopes team. The Institute is a valuable resource offered by Triad Isotopes to consult on clinical and technical issues related to nuclear imaging, assist with reimbursement, develop and present continuing education for technologists and provide guidance on nuclear pharmacy or regulatory mandates.
Steve Heun, Director of Clinical Services for Triad Isotopes is heading up the Institute of Clinical Learning. Steve was previously at DuPont Pharmaceuticals and Bristol Myers Squibb Medical Imaging helping launch I.V Persantine® and Cardiolite®. Steve leads a team of four Clinical Specialists, supporting locations across the Triad delivery area. The group coordinates with the Triad staff of 54 nuclear pharmacists, some of whom serve in the 18 member dedicated PET operations team, and Triad Isotopes Quality and Safety staff, lead by Director, Brigette Nelson.
The White Paper, Diabetes and Heart Disease, Are Your Patients at Risk?, deals with the unique issues facing patients with diabetes and heart disease. The White Paper is the first in a series of clinical subjects that will be of interest to UPPI members and their customers. Triad Isotopes Clinical Advisor, Gary V. Heller, MD, PhD, Director of Nuclear Cardiology, Professor of Medicine and Nuclear Medicine, University of Connecticut School of Medicine, Hartford Hospital states that:
"The number one cause of death in patients with diabetes is coronary artery disease. Identification of at risk patients is critical in determining if a patient with diabetes has coronary artery disease and to what extent. Myocardial Perfusion Imaging can both diagnose and risk stratify patient with diabetes who may have significant CAD and to also assess left ventricular function. Nuclear imaging can be considered an "early warning system" to identify patients with coronary artery disease in time to make important alterations in management".
This clinical information piece provides some discussion points about why diabetes carries a significant risk for patients and for the development of cardiovascular disease specifically CAD. Please direct all questions concerning ICL White Papers to Steve Heun (SHeun@triadisotopes.com).
Triad Isotopes, Inc. owns and operates 19 nuclear pharmacies and 5 cyclotrons located throughout the southeast. The Triad business model combines the best independent, local nuclear pharmacies and cyclotrons with the capital and management experience of a nationwide corporation enabling Triad to continually invest in its procedures, equipment and staff. All of these resources are then deployed across the Triad network of facilities so they can focus solely on patient care in the communities they serve.
Triad Isotopes - Patient focused, Community driven.
www.triadisotopes.com |
09.04.2007 | 
